Fat-Loss Peptides Beyond GLP-1s: The Metabolic Compounds, Honestly Ranked

Fat loss peptides are research compounds studied for their effect on the "energy out" side of metabolism, how efficiently cells oxidise fat, rather than the appetite-suppressing "energy in" side that GLP-1s target. The non-GLP-1 group covered here, 5-Amino-1MQ, SLU-PP-332, L-carnitine, MOTS-c and Tesamorelin, work through targeted, mostly non-stimulant mechanisms studied in cell and animal models.

Everyone is talking about the GLP-1s, and for good reason: nothing else touches them for raw weight loss in the clinical data. But they do one specific thing, target appetite. There is a whole other category of compounds studied on the opposite side of the energy equation, how much fat the body actually burns, and most people lump them in with "fat burners" without understanding that they are a completely different, and far more interesting, class than the old stimulants. This is the honest tour: what the non-GLP-1 metabolic peptides do in the research, which ones are worth your time, and why even the best of them are a multiplier on effort, not a substitute for it.

How does fat loss actually work?

Fat loss comes down to energy balance: take in fewer calories than the body burns and it draws on fat stores to cover the gap. Your body runs on energy, measured in calories. Take in more than you burn and the surplus gets stored as fat; burn more than you take in and your body dips into those fat stores to cover the gap. That is the whole thing, energy in versus energy out, and it is just basic thermodynamics, the same physics that governs every living animal. Nothing escapes it, not a peptide, not a drug, not a superfood. So the only way any compound can affect the balance is by nudging one side of that equation. Appetite drugs like the GLP-1s act on the "energy in" side; everything in this article is studied on the other side, energy out.

So how is that energy-out side studied? In two ways, and both are worth being straight about. In animal models, SLU-PP-332 and 5-Amino-1MQ raised energy expenditure (calories burned at rest) and fat oxidation (the burning of fat for fuel), and in those studies the animals lost fat without eating any less, which is the same direction exercise tilts the balance, so calling them passive passengers is wrong. L-carnitine is more of an enabler: it is the fat-shuttle machinery rather than a driver, and the research suggests it needs demand (training, a deficit) to matter. Now the caveats the marketing skips: the human data is still thin and mostly preclinical (from lab and animal studies, not yet people), the animal effect is nowhere near GLP-1 territory, and diet still dominates. So the research register here is "tilts the balance in models", which is why people build any stack around a real foundation. Real mechanism, not magic, and not a licence to ignore what you eat.

Which non-GLP-1 metabolic peptides are worth knowing?

The non-GLP-1 metabolic peptides worth understanding are 5-Amino-1MQ, SLU-PP-332 and L-carnitine as the core trio, with MOTS-c and Tesamorelin in the same wheelhouse, each studied for a different fat-oxidation mechanism. Here is what the research says about each.

What is 5-Amino-1MQ and how does it work?

5-Amino-1MQ is a small molecule that blocks an enzyme called NNMT, a fat-cell enzyme that consumes NAD+ (a coenzyme cells need to turn food into usable energy) and methyl groups (small chemical tags cells use to switch processes on and off). Inhibit it, and NAD+ is spared inside the fat cell, which the research links to switching on SIRT1 (a cellular "housekeeping" enzyme that NAD+ powers), nudging white fat toward calorie-burning beige fat (a more metabolically active fat that burns energy rather than just storing it), and raising adipocyte (fat-cell) energy expenditure. The headline from the animal work is striking: mice lost fat without eating less (Neelakantan 2018; the related NNMT-knockdown work, Kraus 2014, Nature). It is non-stimulant and orally active in the research, with doses in the literature around 100 to 200 mg a day. The honest limit: the human data is still thin and mostly preclinical, so it is best understood as a promising, well-tolerated research compound rather than a proven drug. In the research it is also the one positioned most naturally alongside a GLP-1.

What is SLU-PP-332, the "exercise mimetic"?

SLU-PP-332 is a research compound described as an "exercise mimetic" because it activates the same metabolic pathways that endurance training does. It activates the ERR family of nuclear receptors (proteins inside the cell that switch genes on), which partner with PGC-1-alpha (the master switch that tells a cell to build more energy machinery) to drive mitochondrial biogenesis (cells building more mitochondria, the tiny power plants inside every cell), fat oxidation and the shift toward oxidative, fatigue-resistant muscle, the same adaptations reported with cardio in the animal work (Billon 2023). Again, non-stimulant, oral, with a short half-life (how long it stays active in the body before it clears) so the research dosing is more frequent. This is the most frontier of the group: the science is genuinely exciting and the human data barely exists yet, so it sits firmly in the "promising and early" bucket. Worth noting it is on the anti-doping radar, so it is not for tested athletes.

What does L-carnitine do for fat metabolism?

L-carnitine is the established workhorse, the only compound here with an approved pharmaceutical version (Carnitor, for genuine carnitine deficiency), and its mechanism is the best understood. Its job is mechanical and well-characterised: it is the shuttle that carries long-chain fats across the mitochondrial membrane so they can be oxidised (Wall 2011). No carnitine, no fat into the furnace. In the research it is used orally (commonly the L-carnitine-L-tartrate form, a few grams a day, often timed with carbs so insulin drives it into muscle) or as a subcutaneous (under the skin) or intramuscular (into the muscle) injection. Two honest caveats: oral loading is genuinely difficult (muscle uptake is the bottleneck, hence the carb timing), and there is a long-running debate about carnitine feeding gut bacteria to produce TMAO, a byproduct made when gut bacteria digest carnitine, linked in some studies to cardiovascular risk (Koeth 2013). One route note: intravenous carnitine infusions (delivered straight into a vein) are used clinically, but we do not recommend the IV route, and large IV infusions are themselves restricted under anti-doping rules.

What about MOTS-c and Tesamorelin?

MOTS-c and Tesamorelin belong in the same wheelhouse but have their own deep-dives. MOTS-c is a mitochondrial-derived peptide (a signalling molecule that comes from the mitochondria themselves) studied for mitochondrial signalling that resembles training adaptations, with a genuine "paradox" worth understanding before running it (the research suggests it depends on laying the foundation first). Full detail in the MOTS-c deep-dive. Tesamorelin is the one studied specifically for visceral fat (the deep abdominal fat packed around the organs), acting through the growth-hormone axis (the body's natural system for releasing growth hormone and responding to it) rather than direct fat-burning; it is covered with the GH peptides.

Metabolic peptides vs clen, T3 and DNP: how do they compare?

Compared with clenbuterol, T3 and DNP, the metabolic peptides chase the same goal, fat oxidation, through targeted non-stimulant mechanisms instead of whole-body force, so they trade peak intensity for a far cleaner risk profile. For decades, "fat burner" meant one of three things, and all three came with a bill.

• Clenbuterol is a stimulant (a beta-2 agonist, meaning it switches on the same receptors adrenaline does) that raises metabolic rate by revving your nervous system. It works, and it also brings tremors, cramps, a racing heart, insomnia, and, with chronic use, real cardiac strain. You feel wired and brittle.
• T3 (liothyronine) is straight exogenous thyroid hormone, meaning thyroid hormone taken from outside rather than made by your own gland. It burns fat efficiently, but it also burns muscle, suppresses your own thyroid (so coming off it is its own ordeal), and pushes your whole system into overdrive.
• DNP (2,4-dinitrophenol) is the extreme. It works by making your cells waste energy as heat, which is brutally effective and genuinely lethal, people die of hyperthermia on it every year, with almost no margin for error. It is the clearest example of brute force with a body count.

And notice what those three have in common: not one of them is even a peptide. Clenbuterol is a stimulant drug, T3 is a thyroid hormone, DNP is an industrial chemical. That is the deeper point. The old way to burn fat meant reaching for blunt, whole-body drugs and chemicals and simply accepting the collateral. The metabolic peptides are a fundamentally different and more targeted class of tool.

The metabolic peptides chase the same goal, more fat oxidised, a higher metabolic ceiling, but they get there through targeted, non-stimulant mechanisms: sparing NAD+ in fat cells, mimicking the adaptations of exercise, improving the fat-shuttle, signalling mitochondrial efficiency. They will not match DNP for raw brute force, and we would not want them to. What they offer is the same direction of travel without the racing heart, the muscle loss, or the genuine danger. That is the real story of peptides as a category: not magic, but the smarter, more precise evolution of tools that used to come with serious collateral. Smarter, not harder, and a great deal safer.

Can you stack metabolic peptides with a GLP-1?

In the research these pair logically with a GLP-1 because they are studied on the burn side while GLP-1s act on the intake side, so the mechanisms do not overlap. A GLP-1 (retatrutide or tirzepatide, see the GLP-1 comparison) targets appetite and the deficit; a metabolic peptide like 5-Amino-1MQ or SLU-PP-332 is studied for fat oxidation and metabolic rate alongside. That is a genuinely non-overlapping pairing, which is the kind of stack that adds up rather than just multiplying side effects. What makes no sense is stacking two appetite suppressants, or expecting a metabolic compound to do a GLP-1's job.

Why doesn't Primogen stock AOD-9604?

Primogen does not stock AOD-9604 because it failed its definitive human obesity trial: it is one of the most-marketed fat-loss peptides on the internet, and the marketing outruns the data. Here is the detail.

AOD-9604 is a fragment of growth hormone designed to isolate the fat-burning region without the growth effects. In rodents it looked excellent. In humans it did not deliver. Its definitive, properly powered trial (a 24-week Phase 2b study, a mid-stage human trial to test whether a drug actually works, in around 500 people, run with diet and exercise) failed to beat placebo, and the company terminated obesity development back in 2007. Its best-ever human result, from a smaller earlier study that was never even peer-reviewed, was about 2 kg versus placebo, against the 15 to 25% body-weight loss the GLP-1s report in their trials. On top of that, it is banned by WADA (the World Anti-Doping Agency, which sets the banned-substance list for sport), the US compounding advisory committee voted against allowing it in late 2024, and the "GRAS safe" badge vendors love to cite (GRAS stands for Generally Recognized As Safe, which a company can simply declare about its own product) is a company self-affirmation, not an FDA endorsement of either safety review or weight-loss benefit. Its safety record is genuinely clean, but a clean safety record on a compound that did not work in trial is not a reason to sell it.

So we do not stock AOD-9604. If a properly designed human trial ever shows it actually works, we will revisit that. Until then, we would rather tell you the famous name does not hold up than take your money for it.

Which fat loss peptide should you research?

It depends on the research angle: 5-Amino-1MQ for a non-stimulant compound studied alongside a GLP-1, SLU-PP-332 for the exercise-mimetic mechanism, and L-carnitine for the established, best-evidenced fat-shuttle. Mapped out:

• Interested in the non-stimulant, NAD+-sparing angle alongside a GLP-1? 5-Amino-1MQ is the cleanest non-stimulant pairing in the research.
• Drawn to the exercise-adaptation angle (mitochondria, endurance, fat oxidation)? SLU-PP-332 is the most interesting, with the caveat that it is early and on the doping list.
• Want the established, evidence-backed workhorse? L-carnitine, used properly (the right form, timed with carbs, alongside training).
• Interested in the mitochondrial-signalling route? Read the MOTS-c deep-dive first, including the paradox.
• Researching the visceral-fat angle specifically? That is Tesamorelin's lane, with the GH peptides.

And whichever you research, keep expectations realistic: the mechanism tilts the energy balance in the models, but the human effect is modest and still being proven, so a solid training-and-diet foundation does the heavy lifting.